SELLAS Life Sciences Group, Inc. SLS Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction at other companies
Other financials
Where this comes from
Reported directly by SELLAS Life Sciences Group, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction.
The official record: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about SELLAS Life Sciences Group, Inc.'s debt issuance costs incurred during noncash or partial noncash transaction.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is SELLAS Life Sciences Group, Inc.'s debt issuance costs incurred during noncash or partial noncash transaction?
- SELLAS Life Sciences Group, Inc. (SLS) reported debt issuance costs incurred during noncash or partial noncash transaction of $0 in Q1 2026.
- How has SELLAS Life Sciences Group, Inc.'s debt issuance costs incurred during noncash or partial noncash transaction changed year-over-year?
- SELLAS Life Sciences Group, Inc.'s debt issuance costs incurred during noncash or partial noncash transaction decreased by 100.0% year-over-year, from $21K to $0.
- What does debt issuance costs incurred during noncash or partial noncash transaction mean?
- This metric represents the costs associated with issuing debt that are settled through non-cash or partial non-cash transactions. It highlights the expenses incurred to secure financing that do not immediately impact cash flow from operations. Tracking these costs is important for assessing the true cost of debt financing and its impact on the balance sheet.